Top

Published in:

01-08-2019 | Breast Cancer | Preclinical study

Elevated serum levels of sialyl Lewis X (sLe^X) and inflammatory mediators in patients with breast cancer

Authors: Evan N. Cohen, Tamer M. Fouad, Bang-Ning Lee, Banu K. Arun, Diane Liu, Sanda Tin, Angelica M. Gutierrez Barrera, Toshihide Miura, Iwao Kiyokawa, Jun Yamashita, Ricardo H. Alvarez, Vicente Valero, Wendy A. Woodward, Yu Shen, Naoto T. Ueno, Massimo Cristofanilli, James M. Reuben

Published in: Breast Cancer Research and Treatment | Issue 3/2019

Abstract

Purpose

The carbohydrate sialyl Lewis^X (sLe^X) mediates cell adhesion, is critical in the normal function of immune cells, and is frequently over-expressed on cancer cells. We assessed the association, differential levels, and prognostic value of sLe^X and inflammatory cytokines/chemokines in breast cancer sera.

Methods

We retrospectively measured sLe^X and a panel of cytokines/chemokines in the sera of 26 non-invasive ductal carcinoma in situ (DCIS), 154 invasive non-metastatic breast cancer (non-MBC), 63 metastatic breast cancer (MBC) patients, and 43 healthy controls. Differences in sLe^X and inflammatory cytokines among and between patient groups and healthy controls were assessed with nonparametric tests and we performed survival analysis for the prognostic potential of sLe^X using a cut-off of 8 U/mL as previously defined.

Results

Median serum sLe^X was significantly higher than controls for invasive breast cancer patients (MBC and non-MBC) but not DCIS. In univariate analysis, we confirmed patients with serum sLe^X > 8 U/mL have a significantly shorter progression-free survival (PFS) (P = 0.0074) and overall survival (OS (P = 0.0003). Similarly, patients with high serum MCP-1 and IP-10 had shorter OS (P = 0.001 and P < 0.001, respectively) and PFS (P = 0.010 and P < 0.001, respectively). sLe^X, MCP-1 and IP-10 remained significant in multivariate survival analysis.

Conclusion

Elevated serum sLe^X was associated with invasive cancer but not DCIS. High serum sLe^X levels were associated with inflammatory mediators and may play a role in facilitating local invasion of breast tumor. Furthermore, serum MCP-1, IP-10 and sLe^X may have prognostic value in breast cancer.

Available only for authorised users

Orr FW, Wang HH, Lafrenie RM, Scherbarth S, Nance DM (2000) Interactions between cancer cells and the endothelium in metastasis. J Pathol 190(3):310–329. https://doi.org/10.1002/(SICI)1096-9896(200002)190:3%3c310:AID-PATH525%3e3.0.CO;2-P CrossRefPubMed

Daniotti JL, Lardone RD, Vilcaes AA (2015) Dysregulated expression of glycolipids in tumor cells: from negative modulator of anti-tumor immunity to promising targets for developing therapeutic agents. Front Oncol 5:300. https://doi.org/10.3389/fonc.2015.00300 CrossRefPubMed

Kannagi R, Izawa M, Koike T, Miyazaki K, Kimura N (2004) Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci 95(5):377–384CrossRef

Zhang Z, Wuhrer M, Holst S (2018) Serum sialylation changes in cancer. Glycoconj J 35(2):139–160. https://doi.org/10.1007/s10719-018-9820-0 CrossRefPubMedPubMedCentral

Ohyama C, Tsuboi S, Fukuda M (1999) Dual roles of sialyl Lewis X oligosaccharides in tumor metastasis and rejection by natural killer cells. EMBO J 18(6):1516–1525. https://doi.org/10.1093/emboj/18.6.1516 CrossRefPubMedPubMedCentral

Matsuura N, Narita T, Mitsuoka C, Kimura N, Kannagi R, Imai T, Funahashi H, Takagi H (1997) Increased level of circulating adhesion molecules in the sera of breast cancer patients with distant metastases. Jpn J Clin Oncol 27(3):135–139CrossRef

Fujita T, Murayama K, Hanamura T, Okada T, Ito T, Harada M, Komatsu A, Koyama H, Kanai T, Maeno K, Mochizuki Y, Hama Y, Ito K, Amano J, Fujimori M (2011) CSLEX (Sialyl Lewis X) is a useful tumor marker for monitoring of breast cancer patients. Jpn J Clin Oncol 41(3):394–399. https://doi.org/10.1093/jjco/hyq190 CrossRefPubMed

Jeschke U, Mylonas I, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K (2005) Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Anticancer Res 25(3A):1615–1622PubMed

Nakagoe T, Fukushima K, Itoyanagi N, Ikuta Y, Oka T, Nagayasu T, Ayabe H, Hara S, Ishikawa H, Minami H (2002) Expression of ABH/Lewis-related antigens as prognostic factors in patients with breast cancer. J Cancer Res Clin Oncol 128(5):257–264. https://doi.org/10.1007/s00432-002-0334-5 CrossRefPubMed

10.

Kurebayashi J, Nomura T, Hirono M, Okubo S, Udagawa K, Shiiki S, Ikeda M, Nakashima K, Tanaka K, Sonoo H (2006) Combined measurement of serum sialyl Lewis X with serum CA15-3 in breast cancer patients. Jpn J Clin Oncol 36(3):150–153. https://doi.org/10.1093/jjco/hyi235 CrossRefPubMed

11.

Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, Tutt A, Taylor-Papadimitriou J, Pinder SE, Burchell JM (2011) Selectin ligand sialyl-Lewis x antigen drives metastasis of hormone-dependent breast cancers. Can Res 71(24):7683–7693. https://doi.org/10.1158/0008-5472.CAN-11-1139 CrossRef

12.

Silva Z, Tong Z, Cabral MG, Martins C, Castro R, Reis C, Trindade H, Konstantopoulos K, Videira PA (2011) Sialyl Lewisx-dependent binding of human monocyte-derived dendritic cells to selectins. Biochem Biophys Res Commun 409(3):459–464. https://doi.org/10.1016/j.bbrc.2011.05.026 CrossRefPubMedPubMedCentral

13.

Narita T, Kawakami-Kimura N, Matsuura N, Hosono J, Kannagi R (1995) Corticosteroids and medroxyprogesterone acetate inhibit the induction of E-selectin on the vascular endothelium by MDA-MB-231 breast cancer cells. Anticancer Res 15(6B):2523–2527PubMed

14.

Barthel SR, Gavino JD, Descheny L, Dimitroff CJ (2007) Targeting selectins and selectin ligands in inflammation and cancer. Expert Opin Therap Targets 11(11):1473–1491. https://doi.org/10.1517/14728222.11.11.1473 CrossRef

15.

Laubli H, Borsig L (2010) Selectins as mediators of lung metastasis. Cancer Microenviron 3(1):97–105. https://doi.org/10.1007/s12307-010-0043-6 CrossRefPubMedPubMedCentral

16.

Laubli H, Borsig L (2010) Selectins promote tumor metastasis. Semin Cancer Biol 20(3):169–177. https://doi.org/10.1016/j.semcancer.2010.04.005 CrossRefPubMed

17.

Portela SV, Martin CV, Romay LM, Cuevas E, Martin EG, Briera AF (2011) sLea and sLex expression in colorectal cancer: implications for tumourigenesis and disease prognosis. Histol Histopathol 26(10):1305–1316PubMed

18.

Iwata T, Nishiyama N, Nagano K, Izumi N, Tsukioka T, Chung K, Hanada S, Inoue K, Kaji M, Suehiro S (2012) Preoperative serum value of sialyl Lewis X predicts pathological nodal extension and survival in patients with surgically treated small cell lung cancer. J Surg Oncol 105(8):818–824. https://doi.org/10.1002/jso.23002 CrossRefPubMed

19.

Ferrajoli A, Lee BN, Schlette EJ, O’Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111(11):5291–5297. https://doi.org/10.1182/blood-2007-12-130120 CrossRefPubMedPubMedCentral

20.

Sozzani P, Arisio R, Porpiglia M, Benedetto C (2008) Is Sialyl Lewis x antigen expression a prognostic factor in patients with breast cancer? Int J Surg Pathol 16(4):365–374. https://doi.org/10.1177/1066896908324668 CrossRefPubMed

21.

Culig Z (2011) Cytokine disbalance in common human cancers. Biochim Biophys Acta 1813(2):308–314. https://doi.org/10.1016/j.bbamcr.2010.12.010 CrossRefPubMed

22.

Walzog B, Gaehtgens P (2000) Adhesion molecules: the path to a new understanding of acute inflammation. News Physiol Sci 15:107–113PubMed

23.

Knupfer H, Preiss R (2007) Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 102(2):129–135. https://doi.org/10.1007/s10549-006-9328-3 CrossRefPubMed

24.

Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY (2003) Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 103(5):642–646. https://doi.org/10.1002/ijc.10833 CrossRefPubMed

25.

Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB, Dirix LY (2004) Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10(21):7157–7162. https://doi.org/10.1158/1078-0432.CCR-04-0812 CrossRefPubMed

26.

Singh JK, Simoes BM, Howell SJ, Farnie G, Clarke RB (2013) Recent advances reveal IL-8 signaling as a potential key to targeting breast cancer stem cells. Breast Cancer Res 15(4):210. https://doi.org/10.1186/bcr3436 CrossRefPubMedPubMedCentral

27.

Goldberg JE, Schwertfeger KL (2010) Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets 11(9):1133–1146CrossRef

28.

Nicolini A, Carpi A, Rossi G (2006) Cytokines in breast cancer. Cytokine Growth Factor Rev 17(5):325–337. https://doi.org/10.1016/j.cytogfr.2006.07.002 CrossRefPubMed

29.

Zhang GJ, Adachi I (1999) Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. Anticancer Res 19(2B):1427–1432PubMed

30.

Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T, Keydar I, Ben-Baruch A (2008) Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine 44(1):191–200. https://doi.org/10.1016/j.cyto.2008.08.002 CrossRefPubMed

31.

Soria G, Ben-Baruch A (2008) The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett 267(2):271–285. https://doi.org/10.1016/j.canlet.2008.03.018 CrossRefPubMed

32.

Lança T, Costa MF, Gonçalves-Sousa N, Rei M, Grosso AR, Penido C, Silva-Santos B (2013) Protective role of the inflammatory CCR32/CCL2 chemokine pathway through recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. J Immunol 190(12):6673–6680. https://doi.org/10.4049/jimmunol.1300434 CrossRefPubMed

33.

Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, Koike M, Inadera H, Matsushima K (2000) Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res 6(8):3282–3289PubMed

34.

Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, Boissiere F, Laune D, Roques S, Lazennec G (2007) Oestrogen receptor negative breast cancers exhibit high cytokine content. Breast Cancer Res 9(1):R15. https://doi.org/10.1186/bcr1648 CrossRefPubMedPubMedCentral

35.

Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ (2018) CXCL9, CXCL10, CXCL11/CXCR35 axis for immune activation—A target for novel cancer therapy. Cancer Treat Rev 63:40–47. https://doi.org/10.1016/j.ctrv.2017.11.007 CrossRefPubMed

36.

Lee JH, Kim HN, Kim KO, Jin WJ, Lee S, Kim HH, Ha H, Lee ZH (2012) CXCL10 promotes osteolytic bone metastasis by enhancing cancer outgrowth and osteoclastogenesis. Can Res 72(13):3175–3186. https://doi.org/10.1158/0008-5472.CAN-12-0481 CrossRef

37.

Liu M, Guo S, Stiles JK (2011) The emerging role of CXCL10 in cancer (Review). Oncol Lett 2(4):583–589. https://doi.org/10.3892/ol.2011.300 CrossRefPubMedPubMedCentral

38.

Bronger H, Singer J, Windmuller C, Reuning U, Zech D, Delbridge C, Dorn J, Kiechle M, Schmalfeldt B, Schmitt M, Avril S (2016) CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase inhibition in advanced serous ovarian cancer. Br J Cancer 115(5):553–563. https://doi.org/10.1038/bjc.2016.172 CrossRefPubMedPubMedCentral

39.

Jafarzadeh A, Fooladseresht H, Nemati M, Assadollahi Z, Sheikhi A, Ghaderi A (2016) Higher circulating levels of chemokine CXCL10 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism. Cancer Biomark 16(4):545–554. https://doi.org/10.3233/CBM-160596 CrossRefPubMed

40.

Toiyama Y, Fujikawa H, Kawamura M, Matsushita K, Saigusa S, Tanaka K, Inoue Y, Uchida K, Mohri Y, Kusunoki M (2012) Evaluation of CXCL10 as a novel serum marker for predicting liver metastasis and prognosis in colorectal cancer. Int J Oncol 40(2):560–566. https://doi.org/10.3892/ijo.2011.1247 CrossRefPubMed

41.

Berres ML, Trautwein C, Schmeding M, Eurich D, Tacke F, Bahra M, Neuhaus P, Neumann UP, Wasmuth HE (2011) Serum chemokine CXC ligand 10 (CXCL10) predicts fibrosis progression after liver transplantation for hepatitis C infection. Hepatology 53(2):596–603. https://doi.org/10.1002/hep.24098 CrossRefPubMed

42.

Piro G, Simionato F, Carbone C, Frizziero M, Malleo G, Zanini S, Casolino R, Santoro R, Mina MM, Zecchetto C, Merz V, Scarpa A, Bassi C, Tortora G, Melisi D (2017) A circulating TH2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Oncoimmunology 6(9):e1322242. https://doi.org/10.1080/2162402X.2017.1322242 CrossRefPubMedPubMedCentral

43.

Dawood S, Ueno NT, Valero V, Woodward WA, Buchholz TA, Hortobagyi GN, Gonzalez-Angulo AM, Cristofanilli M (2012) Identifying factors that impact survival among women with inflammatory breast cancer. Ann Oncol 23(4):870–875. https://doi.org/10.1093/annonc/mdr319 CrossRefPubMed

44.

Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT (2017) Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol 18(4):e228–e232. https://doi.org/10.1016/S1470-2045(17)30192-4 CrossRefPubMedPubMedCentral

45.

Alpaugh ML, Tomlinson JS, Ye Y, Barsky SH (2002) Relationship of sialyl-Lewis(x/a) underexpression and E-cadherin overexpression in the lymphovascular embolus of inflammatory breast carcinoma. Am J Pathol 161(2):619–628. https://doi.org/10.1016/S0002-9440(10)64217-4 CrossRefPubMedPubMedCentral

46.

Conroy RM (2012) What hypotheses do “nonparametric” two-group tests actually test? Stata J 12(2):182–190. https://doi.org/10.1177/1536867x1201200202 CrossRef

47.

Yamashita J, Kobayashi I, Tatematsu K, Sezutsu H, Noda K, Ishihara H (2016) Sandwich elisa using a mouse/human chimeric CSLEX-1 antibody. Clin Chem 62(11):1516–1523. https://doi.org/10.1373/clinchem.2016.260968 CrossRefPubMed

Title: Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer
Authors: Evan N. Cohen
Tamer M. Fouad
Bang-Ning Lee
Banu K. Arun
Diane Liu
Sanda Tin
Angelica M. Gutierrez Barrera
Toshihide Miura
Iwao Kiyokawa
Jun Yamashita
Ricardo H. Alvarez
Vicente Valero
Wendy A. Woodward
Yu Shen
Naoto T. Ueno
Massimo Cristofanilli
James M. Reuben
Publication date: 01-08-2019
Publisher: Springer US
Keywords: Breast Cancer
Breast Cancer
Cytokines
Published in: Breast Cancer Research and Treatment / Issue 3/2019
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-019-05258-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2019

Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial

Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis

Breast cancer risk in relation to plasma metabolites among Hispanic and African American women

Clinical benefit, toxicity and cost of metastatic breast cancer therapies: systematic review and meta-analysis

Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer